Market Cap 108.36B
Revenue (ttm) 11.02B
Net Income (ttm) -535.60M
EPS (ttm) N/A
PE Ratio 28.19
Forward PE 26.84
Profit Margin -4.86%
Debt to Equity Ratio 0.00
Volume 1,004,900
Avg Vol 1,530,454
Day's Range N/A - N/A
Shares Out 256.39M
Stochastic %K 58%
Beta 0.43
Analysts Strong Sell
Price Target $490.60

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
butcalloption
butcalloption Oct. 24 at 2:13 AM
0 · Reply
JohnCosta3086
JohnCosta3086 Oct. 23 at 9:24 PM
Tape is smoking — catalysts near, volume rising! Portfolio: $MSFT $MRNA $HON $VRTX $BF.B Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. MSFT shows relative strength; MRNA is base-building; HON is a stealth accumulator; VRTX offers sector exposure; BF.B provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #MarketPulse #Technical Source: https://stocktwits.com/MarkSavage8573/message/632828492
0 · Reply
KennethVargas1265
KennethVargas1265 Oct. 23 at 7:43 PM
High-conviction cluster — risk-defined entries only! Portfolio: $WYNN $CHRW $BAC $GILD $VRTX Why this cluster: Quiet buy-side interest + improving breadth — watch for volume confirmation. WYNN shows relative strength; CHRW is base-building; BAC is a stealth accumulator; GILD offers sector exposure; VRTX provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #StocksToWatch #Momentum Source:https://stocktwits.com/GaryBrown7417/message/632828520
0 · Reply
VincentWarren7016
VincentWarren7016 Oct. 23 at 4:18 PM
Breaking: momentum cluster forming — watch closely! Portfolio: $VRTX $HLT $BLK $DIS $BHP Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. VRTX shows relative strength; HLT is base-building; BLK is a stealth accumulator; DIS offers sector exposure; BHP provides stability. Execution: Watch: monitor news flow and intraday volume for confirmation before heavy sizing. #MarketPulse #Technical Source: https://stocktwits.com/AngelaBeck8757/message/632828768
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 23 at 2:32 PM
🏛️ 🚀 $VRTX up ⬆️13.79% since our entry $379.72 on Sep 23, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
JCLuckman
JCLuckman Oct. 23 at 12:51 PM
$VRTX Ol Rich Pappy! 💪 Sleep Easy!! $500 by 🎄
0 · Reply
Annbwilliam
Annbwilliam Oct. 23 at 9:44 AM
Everyone wants the next $LLY or $VRTX$VKTX is walking that path before most notice.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 12:09 AM
Enter: $VRTX NOV 14 2025 $430 CALLS Buy in Price: $12.35 - $17.90 Take Profit: $25.07 Stop Bleeding: $10.87 ROI Potential: 103% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
akinyo
akinyo Oct. 22 at 3:49 PM
$VRTX solid!
0 · Reply
Prester_John
Prester_John Oct. 22 at 3:36 PM
$VRTX Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Vertex Pharmaceuticals’ kidney franchise. The company’s innovative approach with povetacicept, which employs a dual BAFF/APRIL blockade, is seen as offering more profound and lasting disease control compared to single-pathway treatments. This is supported by early data indicating significant proteinuria reduction and stabilization of eGFR, suggesting a multi-billion-dollar opportunity with a clear path to becoming a first-in-class treatment. Fein also notes the strategic significance of Vertex’s expansion into primary membranous nephropathy (PMN), a condition with no approved therapies, positioning povetacicept as a potential first-in-class option. https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-promising-kidney-franchise-andrew-feins-buy-rating-on-innovative-povetacicept-and-strategic-expansion-ratings
0 · Reply
Latest News on VRTX
Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 4 weeks ago

Vertex Announces Key Advancements Across Kidney Portfolio


Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 6 weeks ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST


Vertex to Participate in Upcoming September Investor Conferences

Aug 20, 2025, 4:00 PM EDT - 2 months ago

Vertex to Participate in Upcoming September Investor Conferences


Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Aug 12, 2025, 2:34 PM EDT - 2 months ago

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet


Weakness In Vertex Stock Seen As Buying Opportunity

Aug 5, 2025, 2:05 PM EDT - 2 months ago

Weakness In Vertex Stock Seen As Buying Opportunity


Vertex Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:01 PM EDT - 2 months ago

Vertex Reports Second Quarter 2025 Financial Results


How Will VRTX Stock React To Its Upcoming Earnings?

Aug 2, 2025, 12:20 AM EDT - 3 months ago

How Will VRTX Stock React To Its Upcoming Earnings?


Vertex's next-generation cystic fibrosis drug gets EU approval

Jul 1, 2025, 7:46 AM EDT - 4 months ago

Vertex's next-generation cystic fibrosis drug gets EU approval


Vertex to Participate in Upcoming Investor Conferences

May 15, 2025, 4:05 PM EDT - 5 months ago

Vertex to Participate in Upcoming Investor Conferences


butcalloption
butcalloption Oct. 24 at 2:13 AM
0 · Reply
JohnCosta3086
JohnCosta3086 Oct. 23 at 9:24 PM
Tape is smoking — catalysts near, volume rising! Portfolio: $MSFT $MRNA $HON $VRTX $BF.B Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. MSFT shows relative strength; MRNA is base-building; HON is a stealth accumulator; VRTX offers sector exposure; BF.B provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #MarketPulse #Technical Source: https://stocktwits.com/MarkSavage8573/message/632828492
0 · Reply
KennethVargas1265
KennethVargas1265 Oct. 23 at 7:43 PM
High-conviction cluster — risk-defined entries only! Portfolio: $WYNN $CHRW $BAC $GILD $VRTX Why this cluster: Quiet buy-side interest + improving breadth — watch for volume confirmation. WYNN shows relative strength; CHRW is base-building; BAC is a stealth accumulator; GILD offers sector exposure; VRTX provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #StocksToWatch #Momentum Source:https://stocktwits.com/GaryBrown7417/message/632828520
0 · Reply
VincentWarren7016
VincentWarren7016 Oct. 23 at 4:18 PM
Breaking: momentum cluster forming — watch closely! Portfolio: $VRTX $HLT $BLK $DIS $BHP Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. VRTX shows relative strength; HLT is base-building; BLK is a stealth accumulator; DIS offers sector exposure; BHP provides stability. Execution: Watch: monitor news flow and intraday volume for confirmation before heavy sizing. #MarketPulse #Technical Source: https://stocktwits.com/AngelaBeck8757/message/632828768
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 23 at 2:32 PM
🏛️ 🚀 $VRTX up ⬆️13.79% since our entry $379.72 on Sep 23, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
JCLuckman
JCLuckman Oct. 23 at 12:51 PM
$VRTX Ol Rich Pappy! 💪 Sleep Easy!! $500 by 🎄
0 · Reply
Annbwilliam
Annbwilliam Oct. 23 at 9:44 AM
Everyone wants the next $LLY or $VRTX$VKTX is walking that path before most notice.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 12:09 AM
Enter: $VRTX NOV 14 2025 $430 CALLS Buy in Price: $12.35 - $17.90 Take Profit: $25.07 Stop Bleeding: $10.87 ROI Potential: 103% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
akinyo
akinyo Oct. 22 at 3:49 PM
$VRTX solid!
0 · Reply
Prester_John
Prester_John Oct. 22 at 3:36 PM
$VRTX Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Vertex Pharmaceuticals’ kidney franchise. The company’s innovative approach with povetacicept, which employs a dual BAFF/APRIL blockade, is seen as offering more profound and lasting disease control compared to single-pathway treatments. This is supported by early data indicating significant proteinuria reduction and stabilization of eGFR, suggesting a multi-billion-dollar opportunity with a clear path to becoming a first-in-class treatment. Fein also notes the strategic significance of Vertex’s expansion into primary membranous nephropathy (PMN), a condition with no approved therapies, positioning povetacicept as a potential first-in-class option. https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-promising-kidney-franchise-andrew-feins-buy-rating-on-innovative-povetacicept-and-strategic-expansion-ratings
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 22 at 2:58 PM
$VRTX RSI: 64.73, MACD: 6.9124 Vol: 12.32, MA20: 407.76, MA50: 397.88 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
cuttail07
cuttail07 Oct. 22 at 2:56 PM
$VRTX ARCT with disappointing results, further solidifying Vertex’s dominance in CF.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 11:21 PM
Enter: $VRTX NOV 14 2025 $430 CALLS Buy in Price: $12.35 - $16.90 Take Profit: $15.68 Stop Bleeding: $10.87 ROI Potential: 27% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 11:14 PM
$VRTX Share Price: $426.25 Contract Selected: Nov 14, 2025 $430 Calls Buy Zone: $10.62 – $13.12 Target Zone: $19.94 – $24.37 Potential Upside: 77% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 8:04 PM
$VRTX $450 coming to a theatre near you...
0 · Reply
svertical1
svertical1 Oct. 21 at 5:45 PM
$VRTX Bodes repeating…..$460 for gap fill
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 3:24 PM
$VRTX looking good 0:)
0 · Reply
svertical1
svertical1 Oct. 21 at 3:09 PM
$VRTX Once again WS Analysts are missing the significance of this and are way under estimating the value of Vertex’s pipeline.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 11:50 PM
Enter: $VRTX NOV 14 2025 $420 CALLS Buy in Price: $17.42 - $19.50 Take Profit: $28.74 Stop Bleeding: $15.33 ROI Potential: 65% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JoeB07
JoeB07 Oct. 20 at 9:14 PM
$INSM $LQDA $UTHR $VRTX granted this is a sample size. Key data- these pulmonologists each wrote an average of 9x prescriptions which covered 10% of their patients. So in this sample 10% of eligible NCFB patients got a prescription in the first month post launch? That's pretty d8mn impressive. Imagine how many more they will reach in Q4. Excited to see Q4 numbers at JPM in January....
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 20 at 4:10 PM
$VRTX Take us higher... nice breaking point here.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 19 at 9:51 PM
Enter: $VRTX NOV 14 2025 $420 CALLS Buy in Price: $16.20 - $19.20 Take Profit: $23.33 Stop Bleeding: $14.26 ROI Potential: 44% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply